Patient characteristics
| Variable . | AML CR1, N (%) . | CML CP1, N (%) . |
|---|---|---|
| Number of patients | 1742 | 2576 |
| Number of centers | 193 | 188 |
| Geographic region of transplant team | ||
| United States, Canada | 600 (34) | 872 (34) |
| Europe | 589 (34) | 829 (32) |
| Other | 553 (32) | 875 (34) |
| Median age, y (range) | 29 (< 1-60) | 36 (< 1-60) |
| Age, y | ||
| < 10 | 226 (13) | 44 (2) |
| 10-19 | 300 (17) | 199 (8) |
| 20-29 | 340 (20) | 496 (19) |
| 30-39 | 366 (21) | 791 (31) |
| 40-49 | 357 (20) | 737 (29) |
| > 50 | 153 (9) | 309 (12) |
| Male | 915 (53) | 1500 (58) |
| Karnofsky score pretransplant ≥ 90 | 1481 (86) | 2309 (90) |
| History of smoking before transplant | ||
| Yes | 416 (24) | 645 (25) |
| No | 1085 (62) | 1510 (59) |
| Missing | 241 (14) | 421 (16) |
| Interval from diagnosis to transplant, mo | ||
| < 6 | 1191 (68) | 618 (24) |
| ≥ 6 | 549 (32) | 1958 (76) |
| Year of transplant | ||
| 1986-1995 | 871 (50) | 1291 (50) |
| 1996-2005 | 871 (50) | 1285 (50) |
| Donor source | ||
| HLA-matched sibling | 1460 (84) | 1954 (76) |
| Other related | 96 (6) | 180 (7) |
| Unrelated | 186 (11) | 442 (17) |
| Graft type | ||
| Bone marrow | 1404 (81) | 2215 (86) |
| Peripheral blood | 338 (19) | 361 (14) |
| Donor or recipient CMV positive | 1263 (73) | 1801 (70) |
| Cycles of prior chemo induction/consolidation (for AML) | ||
| 1-2 | 617 (35) | |
| > 2 | 526 (30) | |
| Missing | 599 (34) | |
| Pretransplant therapy (for CML) | ||
| Interferon ± other | 919 (36) | |
| Hydroxyurea ± other | 1394 (54) | |
| Other | 168 (7) | |
| None | 55 (2) | |
| Missing | 40 (1) | |
| GVHD prophylaxis | ||
| Ex vivo T-cell depletion | 60 (3) | 60 (2) |
| ATG, campath, or anti-CD3 antibody | 98 (6) | 211 (8) |
| MTX + CSA ± other | 1165 (67) | 1874 (73) |
| Other | 418 (24) | 429 (17) |
| G-CSF/GM-CSF to promote engraftment | ||
| Yes | 564 (32) | 891 (35) |
| No | 1085 (62) | 1500 (58) |
| Missing | 93 (5) | 185 (7) |
| Cumulative incidence of acute GVHD (grades 2-4) at day 100, % (95% CI) | 33 (31-35) | 42 (40-44) |
| Cumulative incidence of chronic GVHD at 3 y, % (95% CI) | 32 (30-35) | 46 (44-48) |
| Median follow-up of survivors, y (range) | 7 (< 1-21) | 8 (< 1-19) |
| Variable . | AML CR1, N (%) . | CML CP1, N (%) . |
|---|---|---|
| Number of patients | 1742 | 2576 |
| Number of centers | 193 | 188 |
| Geographic region of transplant team | ||
| United States, Canada | 600 (34) | 872 (34) |
| Europe | 589 (34) | 829 (32) |
| Other | 553 (32) | 875 (34) |
| Median age, y (range) | 29 (< 1-60) | 36 (< 1-60) |
| Age, y | ||
| < 10 | 226 (13) | 44 (2) |
| 10-19 | 300 (17) | 199 (8) |
| 20-29 | 340 (20) | 496 (19) |
| 30-39 | 366 (21) | 791 (31) |
| 40-49 | 357 (20) | 737 (29) |
| > 50 | 153 (9) | 309 (12) |
| Male | 915 (53) | 1500 (58) |
| Karnofsky score pretransplant ≥ 90 | 1481 (86) | 2309 (90) |
| History of smoking before transplant | ||
| Yes | 416 (24) | 645 (25) |
| No | 1085 (62) | 1510 (59) |
| Missing | 241 (14) | 421 (16) |
| Interval from diagnosis to transplant, mo | ||
| < 6 | 1191 (68) | 618 (24) |
| ≥ 6 | 549 (32) | 1958 (76) |
| Year of transplant | ||
| 1986-1995 | 871 (50) | 1291 (50) |
| 1996-2005 | 871 (50) | 1285 (50) |
| Donor source | ||
| HLA-matched sibling | 1460 (84) | 1954 (76) |
| Other related | 96 (6) | 180 (7) |
| Unrelated | 186 (11) | 442 (17) |
| Graft type | ||
| Bone marrow | 1404 (81) | 2215 (86) |
| Peripheral blood | 338 (19) | 361 (14) |
| Donor or recipient CMV positive | 1263 (73) | 1801 (70) |
| Cycles of prior chemo induction/consolidation (for AML) | ||
| 1-2 | 617 (35) | |
| > 2 | 526 (30) | |
| Missing | 599 (34) | |
| Pretransplant therapy (for CML) | ||
| Interferon ± other | 919 (36) | |
| Hydroxyurea ± other | 1394 (54) | |
| Other | 168 (7) | |
| None | 55 (2) | |
| Missing | 40 (1) | |
| GVHD prophylaxis | ||
| Ex vivo T-cell depletion | 60 (3) | 60 (2) |
| ATG, campath, or anti-CD3 antibody | 98 (6) | 211 (8) |
| MTX + CSA ± other | 1165 (67) | 1874 (73) |
| Other | 418 (24) | 429 (17) |
| G-CSF/GM-CSF to promote engraftment | ||
| Yes | 564 (32) | 891 (35) |
| No | 1085 (62) | 1500 (58) |
| Missing | 93 (5) | 185 (7) |
| Cumulative incidence of acute GVHD (grades 2-4) at day 100, % (95% CI) | 33 (31-35) | 42 (40-44) |
| Cumulative incidence of chronic GVHD at 3 y, % (95% CI) | 32 (30-35) | 46 (44-48) |
| Median follow-up of survivors, y (range) | 7 (< 1-21) | 8 (< 1-19) |
CMV indicates cytomegalovirus; ATG, antithymocyte globulin; MTX, methotrexate; CSA, cyclosporine; G-CSF, granulocyte colony-stimulating factor; and GM-CSF, granulocyte macrophage colony stimulating factor.